JP6113850B2 - がん性組織の治療およびがん性腫瘍の再発および転移を予防するための医薬組成物の調製のためのヘモグロビン系酸素運搬体の使用方法 - Google Patents
がん性組織の治療およびがん性腫瘍の再発および転移を予防するための医薬組成物の調製のためのヘモグロビン系酸素運搬体の使用方法 Download PDFInfo
- Publication number
- JP6113850B2 JP6113850B2 JP2015536905A JP2015536905A JP6113850B2 JP 6113850 B2 JP6113850 B2 JP 6113850B2 JP 2015536905 A JP2015536905 A JP 2015536905A JP 2015536905 A JP2015536905 A JP 2015536905A JP 6113850 B2 JP6113850 B2 JP 6113850B2
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- hemoglobin
- cells
- cancer
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/42—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
HIF1a:
SEQ NO. 1: フォワードプライマー: 5-GGCGCGAACGACAAGAAAAAG-3 (420-440)
SEQ NO. 2: リバースプライマー: 5-CCTTATCAAGATGCGAACTCACA-3 (21-44)
SEQ NO. 3: フォワードプライマー: CAGAGCAGGAAAAGGAGTCA (2414-2433)
SEQ NO. 4: リバースプライマー: AGTAGCTGCATGATCGTCTG (2645-2625)
SEQ NO. 5: フォワードプライマー: 5′-AATGGAATGGAGCAAAAGACAATT-3′ (2694-2720)
SEQ NO. 6: リバースプライマー: 5′-ATTGATTGCCCCAGCAGTCTAC-3′ (2764-2743)
VEGF:
SEQ NO. 7: フォワードプライマー: GCTACTGCCATCCAATCGAG (1187-1206)
SEQ NO. 8: リバースプライマー: CTCTCCTATGTGCTGGCCTT (1395-1376)
SEQ NO. 9: フォワードプライマー: 5′-CTCTCTCCCTCATCGGTGACA-3′ (3146-3167)
SEQ NO. 10: リバースプライマー: 5′-GGAGGGCAGAGCTGAGTGTTAG-3′ (3202-3223)
SEQ NO. 11: フォワードプライマー: ACTGCCATCCAATCGAGACC (1190-1209)
SEQ NO. 12: リバースプライマー: GATGGCTGAAGATGTACTCGATCT (1265-1241)
INOS:
SEQ NO. 13: フォワードプライマー: 5'-ACAACAAATTCAGGTACGCTGTG-3' (2111-2137)
SEQ NO. 14: リバースプライマー: 5'-TCTGATCAATGTCATGAGCAAAGG-3 (2194-2171)
SEQ NO. 15: フォワードプライマー: GTTCTCAAGGCACAGGTCTC (121-140)
SEQ NO. 16: リバースプライマー: GCAGGTCACTTATGTCACTTATC (225-247)
ET1:
SEQ NO. 17: フォワードプライマー: TGCCAAGCAGGAAAAGAACT (701-720)
SEQ NO. 18: リバースプライマー: TTTGACGCTGTTTCTCATGG (895-876)
HSP90:
SEQ NO. 19: フォワードプライマー: TTCAGACAGAGCCAAGGTGC (640-659)
SEQ NO. 20: リバースプライマー: CAATGACATCAACTGGGCAAT (807-787)
SEQ NO. 21: フォワードプライマー: GGCAGTCAAGCACTTTTCTGTAG (1032-1054)
SEQ NO. 22: リバースプライマー: GTCAACCACACCACGGATAAA (1230-1210)
VHL:
SEQ NO. 23: フォワードプライマー: ATTAGCATGGCGGCACACAT (2806-2825)
SEQ NO. 24: リバースプライマー: TGGAGTGCAGTGGCATACTCAT (2921-2900)
(実施例5)
Claims (9)
- がん性組織の治療およびがん性腫瘍の再発および転移を予防するための医薬組成物の調製のためのヘモグロビン系酸素運搬体の使用方法であって、
前記組成物は、投与が必要な被験体に対して単独で、または少なくとも一つの化学療法剤とを組み合わせて投与され、
がん性組織または腫瘍の除去を行う間および行った後に前記被験体に投与される、
ヘモグロビン系酸素運搬体の使用方法。 - 前記がん性組織または腫瘍が、肝臓がん、上咽頭がん、脳がん、大腸がん、肺がん、頭頸部がん、乳がんおよび白血病である、請求項1に記載の使用方法。
- 前記がん性組織または腫瘍が低酸素状態である、請求項1に記載の使用方法。
- 前記ヘモグロビン系酸素運搬体が、分子量60−70kDaの架橋四量体ヘモグロビンであり、および0.05−0.4%の濃度のN−アセチルシステインを添加しながら熱処理した後の熱安定性である、請求項1に記載の使用方法。
- 前記組成物が血管収縮作用を有する不純物およびタンパク質不純物を含まず、非発熱性、エンドトキシンフリー、リン脂質フリー、およびストローマフリーであり、前記熱処理および添加したN―アセチルシステインとの反応により5%未満のメトヘモグロビン濃度である、請求項1に記載の使用方法。
- 前記組成物は、約0.2−1.2g/kg体重の範囲で、および10ml/時/kg体重未満の割合で、点滴によって投与される、請求項1に記載の使用方法。
- 前記少なくとも一つの化学療法剤は、5−フルオロウラシル、ボルテゾミブ、ドキソルビシン、シスプラチン、またはその任意の組み合わせから選択されている、請求項1に記載の使用方法。
- 前記ヘモグロビン系酸素運搬体は、がん性組織塊または腫瘍に酸化ストレスおよびショックを与え、自己再生能および腫瘍形成能を有する細胞を含む前記がん性組織または腫瘍の細胞にアポトーシスを誘発するように前記腫瘍組織または腫瘍を前記化学療法剤に感作するために、前記少なくとも1つの化学療法剤とともに、補助的な療法として投与される、請求項1に記載の使用方法。
- 前記自己再生能と腫瘍形成能をもつ細胞ががん幹細胞および/またはがん始原細胞である、請求項8に記載の使用方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261712853P | 2012-10-12 | 2012-10-12 | |
US61/712,853 | 2012-10-12 | ||
US13/713,031 | 2012-12-13 | ||
US13/713,031 US20140106004A1 (en) | 2012-10-12 | 2012-12-13 | Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence |
PCT/US2013/064418 WO2014059199A1 (en) | 2012-10-12 | 2013-10-11 | Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015534946A JP2015534946A (ja) | 2015-12-07 |
JP2015534946A5 JP2015534946A5 (ja) | 2016-12-01 |
JP6113850B2 true JP6113850B2 (ja) | 2017-04-12 |
Family
ID=50475529
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015536905A Expired - Fee Related JP6113850B2 (ja) | 2012-10-12 | 2013-10-11 | がん性組織の治療およびがん性腫瘍の再発および転移を予防するための医薬組成物の調製のためのヘモグロビン系酸素運搬体の使用方法 |
Country Status (22)
Country | Link |
---|---|
US (2) | US20140106004A1 (ja) |
EP (1) | EP2906222A4 (ja) |
JP (1) | JP6113850B2 (ja) |
KR (1) | KR20150065881A (ja) |
CN (1) | CN104717966B (ja) |
AP (1) | AP2015008315A0 (ja) |
AR (1) | AR093023A1 (ja) |
AU (1) | AU2013329121B2 (ja) |
BR (1) | BR112015007475A2 (ja) |
CA (1) | CA2884521C (ja) |
CL (1) | CL2015000897A1 (ja) |
EA (1) | EA201500301A1 (ja) |
HK (1) | HK1206281A1 (ja) |
IL (1) | IL237763A (ja) |
MA (1) | MA37994A2 (ja) |
MX (1) | MX367562B (ja) |
PH (1) | PH12015500562B1 (ja) |
SG (3) | SG10201607846PA (ja) |
TW (1) | TW201414489A (ja) |
UY (1) | UY35082A (ja) |
WO (1) | WO2014059199A1 (ja) |
ZA (1) | ZA201501949B (ja) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6392855B2 (ja) * | 2013-05-13 | 2018-09-19 | ビジョン グローバル ホールディングス リミテッドVision Global Holdings Ltd. | がん治療および診断イメージングのための修飾ヘモグロビンベース系治療剤を含む医薬組成物 |
CN106536056B (zh) | 2014-06-13 | 2021-07-16 | 儿童医学中心公司 | 分离线粒体的产品和方法 |
US9814759B2 (en) * | 2014-07-02 | 2017-11-14 | Cheer Global Ltd. | Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment |
WO2017095946A1 (en) | 2015-11-30 | 2017-06-08 | Flagship Pioneering, Inc. | Methods and compositions relating to chondrisomes |
EP3735976A3 (en) * | 2016-01-15 | 2021-01-27 | The Children's Medical Center Corporation | Therapeutic use of mitochondria and combined mitochondrial agents |
US20230190947A1 (en) * | 2016-06-21 | 2023-06-22 | Therapure Biopharma Inc. | Hemoglobin-Targeted Drug Delivery For The Treatment of Cancer |
US11197872B2 (en) | 2017-04-21 | 2021-12-14 | Lunella Biotech, Inc. | Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs) |
WO2018195446A1 (en) * | 2017-04-21 | 2018-10-25 | Lisanti Michael P | Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy |
MX2019013735A (es) | 2017-05-19 | 2020-01-15 | Lunella Biotech Inc | Antimitoscinas: inhibidores especificos de la biogenesis mitocondrial para erradicar celulas madre cancerosas. |
EP3624897A4 (en) | 2017-05-19 | 2021-07-14 | Lunella Biotech, Inc. | COMPANION DIAGNOSIS FOR MITOCHONDRIAL INHIBITORS |
CU20190106A7 (es) | 2017-06-26 | 2020-11-30 | Lunella Biotech Inc | Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas |
WO2019124423A1 (ja) * | 2017-12-19 | 2019-06-27 | 国立大学法人 岡山大学 | がんの進行抑制、治療、予防及び/又は再発予防剤 |
CN111558032B (zh) * | 2020-05-19 | 2023-08-22 | 中国科学院宁波材料技术与工程研究所 | 一种蛋白纳米药物及其制备方法与应用 |
CN114344263B (zh) * | 2022-02-21 | 2023-08-01 | 杭州普略生物科技有限公司 | 一种用于靶向巨噬细胞增强肿瘤治疗效果的纳米蛋白胶束及其制备方法和应用 |
KR20230141306A (ko) | 2022-03-31 | 2023-10-10 | 충남대학교산학협력단 | 저산소증 완화능을 갖는 페길화 헤모글로빈 나노클러스터를 포함하는 항암 화학-광역학 치료용 조성물 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5478806A (en) * | 1989-11-22 | 1995-12-26 | Enzon, Inc. | Enhancement of antitumor therapy with hemoglobin-based conjugates |
CA2236344A1 (en) * | 1998-04-30 | 1999-10-30 | Hemosol Inc. | Hemoglobin-haptoglobin complexes |
US20050164915A1 (en) * | 2002-04-01 | 2005-07-28 | Sangart, Inc. | Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin |
CN1741821B (zh) * | 2002-10-29 | 2011-08-10 | 恩根尼公司 | 用于癌症治疗的组合物 |
CA2750639A1 (en) * | 2009-01-23 | 2010-07-29 | Cancer Research Technology Limited | Hedgehog pathway inhibitors |
LT2440239T (lt) * | 2009-06-09 | 2017-12-11 | Prolong Pharmaceuticals, LLC | Hemoglobino kompozicijos |
EP2451459B1 (en) * | 2009-07-07 | 2017-11-22 | Normoxys, Inc. | Method of reducing multi-drug resistance using inositol tripyrophosphate |
US8808748B2 (en) * | 2010-04-20 | 2014-08-19 | Vindico NanoBio Technology Inc. | Biodegradable nanoparticles as novel hemoglobin-based oxygen carriers and methods of using the same |
US7989593B1 (en) * | 2010-05-27 | 2011-08-02 | Bing Lou Wong | Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof |
US7932356B1 (en) * | 2010-06-23 | 2011-04-26 | Bing Lou Wong | Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition |
US20110319332A1 (en) * | 2010-06-23 | 2011-12-29 | Bing Lou Wong | Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition |
US8048856B1 (en) * | 2010-06-23 | 2011-11-01 | Billion King, Ltd. | Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition |
-
2012
- 2012-12-13 US US13/713,031 patent/US20140106004A1/en not_active Abandoned
-
2013
- 2013-10-11 CA CA2884521A patent/CA2884521C/en active Active
- 2013-10-11 EP EP13844670.3A patent/EP2906222A4/en not_active Ceased
- 2013-10-11 JP JP2015536905A patent/JP6113850B2/ja not_active Expired - Fee Related
- 2013-10-11 AP AP2015008315A patent/AP2015008315A0/xx unknown
- 2013-10-11 BR BR112015007475A patent/BR112015007475A2/pt not_active IP Right Cessation
- 2013-10-11 SG SG10201607846PA patent/SG10201607846PA/en unknown
- 2013-10-11 CN CN201380053346.1A patent/CN104717966B/zh active Active
- 2013-10-11 AU AU2013329121A patent/AU2013329121B2/en not_active Ceased
- 2013-10-11 KR KR1020157012185A patent/KR20150065881A/ko active Search and Examination
- 2013-10-11 SG SG10201608747RA patent/SG10201608747RA/en unknown
- 2013-10-11 WO PCT/US2013/064418 patent/WO2014059199A1/en active Application Filing
- 2013-10-11 EA EA201500301A patent/EA201500301A1/ru unknown
- 2013-10-11 MA MA37994A patent/MA37994A2/fr unknown
- 2013-10-11 SG SG11201502133SA patent/SG11201502133SA/en unknown
- 2013-10-11 MX MX2015004512A patent/MX367562B/es active IP Right Grant
- 2013-10-14 UY UY35082A patent/UY35082A/es not_active Application Discontinuation
- 2013-10-14 TW TW102136951A patent/TW201414489A/zh unknown
- 2013-10-15 AR ARP130103741A patent/AR093023A1/es unknown
-
2014
- 2014-06-19 US US14/308,725 patent/US9056098B2/en active Active
-
2015
- 2015-03-16 PH PH12015500562A patent/PH12015500562B1/en unknown
- 2015-03-16 IL IL237763A patent/IL237763A/en active IP Right Grant
- 2015-03-20 ZA ZA2015/01949A patent/ZA201501949B/en unknown
- 2015-04-09 CL CL2015000897A patent/CL2015000897A1/es unknown
- 2015-07-24 HK HK15107105.0A patent/HK1206281A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6113850B2 (ja) | がん性組織の治療およびがん性腫瘍の再発および転移を予防するための医薬組成物の調製のためのヘモグロビン系酸素運搬体の使用方法 | |
AU2019264092B2 (en) | Targeting M2-like tumor-associated macrophages by using melittin-based pro-apoptotic peptide | |
Yang et al. | TWEAK protects cardiomyocyte against apoptosis in a PI3K/AKT pathway dependent manner | |
JP7042496B2 (ja) | Runx阻害剤 | |
TWI633118B (zh) | 用於癌症標靶治療之包含基於重組血紅素蛋白或次單元之治療劑的醫藥組成物 | |
Tang et al. | Modified chitosan for effective renal delivery of siRNA to treat acute kidney injury | |
ES2913073T3 (es) | Direccionamiento del sistema inmunitario innato para inducir tolerancia a largo plazo y resolver la acumulación de macrófagos en aterosclerosis | |
JP6100252B2 (ja) | 異なる治療用途のための熱安定性酸素キャリアを含有する医薬組成物 | |
EP3962365A1 (en) | Prophylactic and therapeutic use of mitochondria and combined mitochondrial agents | |
Liu et al. | Environmentally self-adaptative nanocarriers suppress glioma proliferation and stemness via codelivery of shCD163 and doxorubicin | |
US12059429B2 (en) | Hornerin: a novel non-VEGF mediated angiogenic protein expressed in both human and mouse angiogenic endothelial cells and human pancreatic cancer cells | |
JP2020501513A (ja) | 治療用多標的コンストラクトおよびその使用 | |
JP2023503923A (ja) | ポリマーをベースとする抗腫瘍剤としてのカルバザート活性化ポリビニルアルコール(pvac) | |
Hung et al. | Recombinant viral protein VP1 suppresses HER-2 expression and migration/metastasis of breast cancer | |
KR102133205B1 (ko) | PNA-pHLIP 접합체를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물 | |
Rahmy | Overcoming Resistance to Immune Checkpoint Blockade Therapy | |
JP2016179973A (ja) | 化合物またはその塩および医薬組成物 | |
WO2020227682A1 (en) | Treating cancer | |
Miyauchi | The Role of Neuropilin 1 in Glioma Associated Microglia and Macrophages | |
JP2021116243A (ja) | Nashを治療又は予防するための薬剤 | |
KR20190123147A (ko) | 세포에서의 자가포식작용 억제용 조성물, 및 이를 포함하는 종양성 질환의 예방 또는 치료용, 또는 항암제 내성 억제용 약학적 조성물 | |
BR112015015115B1 (pt) | Composto, uso, composição farmacêutica anti-tumoral, construção gênica para a expressão de polipeptídeo, processo de produção, processo para avaliação de células tumorais, método de sensibilização de células tumorais a quimioterápicos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161011 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161011 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20161021 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20161110 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161122 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170127 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170214 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170315 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6113850 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |